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ically ill adults.
Materials and methods: Single-center, pilot study of a convenience sample of ICU adults with delirium treated
with low-dose IV haloperidol. Patients were evaluated for deliriumwith the ICDSC every 8 h. Serum haloperidolKeywords:Purpose: To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in crit-
concentrations were collected on ICU days 2–6, CYP2D6 and CYP3A4 genotypes were characterized and patients
were categorized as extensive (EM), intermediate (IM) or poor metabolizers (PM).
Results: The 22 patients (median age 67 [IQR 48,77] years;median APACHE III 81[IQR 54,181]; CYP2D6 [EM=12,
IM= 7, PM= 3], CYP3A [EM= 18, IM= 4]) received a median [IQR] daily haloperidol dose of 3.0 [2.4, 4.5] mg.
After adjusting for age, SOFA, and ICU day, neither an association between CYP2D6 (IM p = .67/PM p = .25) or
CYP3A4 (IM p=.44)metabolizer status and serumhaloperidol concentrationswas found. After adjusting for age,
SOFA, and ICU day, neither an association between daily haloperidol dose (p= .77) or ICDSC score (p= .13) and
serum haloperidol concentrations was found. No patient experienced QTc interval prolongation (≥500 ms).
Conclusions: This pilot study, the first to evaluate the pharmacogenomic response of low-dose haloperidol when
used to treat delirium in the ICU, suggests CYP2D6/CYP3A4metabolizer status does not affect the serumhaloper-
idol concentrations.






Haloperidol is frequently administered to critically ill adults to pre-
vent and/or treat delirium despite evidence from randomized, con-
trolled trials that it neither prevents or resolves delirium nor improves
important outcomes like mortality or post-intensive care unit (ICU)
cognition [1–5]. The authors of the REDUCE trialwhere intravenous hal-
operidol (up to 8mg daily) was administered to prevent delirium in the
ICU postulate low haloperidol serum concentrations may have influ-
enced the lack of benefit with haloperidol they observed [6].), m.vanderjagt@erasmusmc.nl
n@northeastern.edu
ch@erasmusmc.nl (B.C.P. Koch),
@erasmusmc.nlHaloperidol is metabolized by both the CYP2D6 and CYP3A4 isoen-
zyme systems [7]. Polymorphisms to either isoenzyme are common in
the general population and vary by race. Among healthy adult Cauca-
sians, extensive, intermediate and poor metabolizer prevalence is 50%,
40% and 10%, respectively, for CYP2D6 and 55%, 32% and 8% for
CYP3A4 [8]. While critical illness may alter the metabolizer status of
these isoenzymes, the prevalence of CYP2D6 and CYP3A4 polymor-
phism in the ICU remains unclear. Importantly, commonly administered
ICU medications compete with haloperidol for the same CYP2D6/3A4
metabolic pathway or may act as CYP2D6/3A4 inducers or inhibitors
[9]. Pharmacogenomic variability may therefore be an important con-
tributor to haloperidol response when it is used to treat delirium in
the ICU.
Although the pharmacogenomic characteristics of haloperidol have
been evaluated in patients with major psychiatric disorders [10], these
properties have not been evaluated in critically ill adults receiving
low-dose haloperidol for the treatment of delirium [1,4]. This data is
204 Z. Trogrlić et al. / Journal of Critical Care 57 (2020) 203–207important when identifying the optimal dose of haloperidol that should
be evaluated in future ICU delirium treatment trials andmay help guide
clinicians seeking to individualize haloperidol dosing for their patients
clinically-important delirium symptom(s) (e.g., agitation) [11]. We
therefore sought to characterize the pharmacogenetic characteristics
of low-dose haloperidol in critically ill adults with delirium.
2. Material and methods
2.1. Study design and population
This single-center, pilot study was conducted in the adult intensive
care units at Erasmus University Medical Centre, Rotterdam, NL. The
study was approved by the Institutional Review Board and informed
consentwas obtained fromeach patient's legally authorized representa-
tive given all patients had delirium. A convenience sample of adults
with delirium [Intensive Care Delirium Screening Checklist (ICDSC ≥4)
[12], expected to be admitted to the ICU ≥48 h, and administered intra-
venous (IV) haloperidol according to an institutional delirium treat-
ment protocol were evaluated for study participation between
October 2014 and April 2017. Patients were excluded if they had been
treated with haloperidol in the 24 h prior to ICU admission, had end
stage liver failure or acute alcohol withdrawal, were admitted because
of an acute neurologic injury, had a history of severe dementia, parkin-
sonism and/or psychosis, had a baselineQTc interval≥450msec, orwere
receiving a medication with the potential to induce either CYP2A6 and/
or CYP3A4 concentrations (i.e., bosentan, carbamazepine, efavirenz,
etravirine, lopinavir, nevirapine, phenobarbital, phenytoin, rifabutin, ri-
tonavir, rifampicin).
2.2. Data collection
The following baseline data was collected: gender, age, APACHE III
score, body mass index (BMI), serum blood urea nitrogen, ICDSC
score, QTc interval (based on ECG evaluation) and CYP2D6 and
CYP3A4 isoenzyme concentrations. The following daily data was col-
lected: daily change in ICDSC score, total dose of haloperidol adminis-
tered, SOFA (Sequential Organ Failure Assessment) score, QTc interval,
ICU use of medications known to inhibit CYP2D6 (i.e., amiodarone, ci-
metidine, fluoxetine, metoclopramide,metoprolol, paroxetine, and pro-
pranolol) and/or CYP3A4 (i.e., alprazolam, amiodarone, aripiprazole,
clozapine, diazepam, erythromycin,fluconazole, melatonin,midazolam,
quetiapine, risperidone, verapamil, voriconazole, zolpidem, and
zopiclone) activity [13,14].
Both delirium screening (by the ICU bedside nurse using the ICDSC
every 8 h) and reduction efforts were well-established in all study
ICUs [15,16]. The investigative team conducted regular spot-checks of
nurse ICDSC assessments, offering additional training to nurses when
required. The ICU delirium treatment protocol advocated haloperidol
treatment for all patients who developed delirium at a starting dose of
1mg IV q8h [0.5mg IV q8h if age ≥ 80 years old; 2mg IV q8h if agitation
present] within 8 h of deliriumdetection. If deliriumwas still present 24
h later the IV haloperidol was increased by 0.5 mg to a maximum of 2
mg IV q8h. The haloperidol dose was decreased when the ICDSC was
≤3 for more than 24 h, and was stopped when the ICDSC was ≤3 for
more than 48 h.
CYP3A4 and CYP2D6 patient genotyping was performed using
Autogenomics INFINITY genotyping platform (Carlsbad, USA) and
detected CYP2D6 *2 (2850C N T), *2A (−1584C N G), *3 (2549G N A),
*5 (deletion), *6 (1707delT), *7 (2935A N C), *8 (1758G N T), *9
(2615_2617delAAG), *10 (100NT), *12 (124G N A), *14 (1758G N A),
*17 (1023C N T), *29 (1659G N A) and gene duplication and
for CYP3A4 variants *1B (−392A N G), *2 (15,713 T N C)_, *3 (23171C
N T), *12 (21896C N T), *17 (15,615 T N C) and *22 (15389C N T)
(www.pharmvar.org). For each isoenzyme, patients were classified ac-
cording to the number of active enzyme alleles present: poormetabolizers (PM; two defective alleles), intermediate metabolizers
(IM, 2 decreased activity alleles or 1 active and 1 inactive allele), exten-
sive metabolizers (EM) and ultra-rapid metabolizers (UM, gene dupli-
cation positive in absence of a CYP2D6 null allele).
Blood samples for serum haloperidol concentration evaluation were
drawn from an arterial line before the administration of each morning
dose on days 2, 3, 4, 5, and 6 (end of study) or until haloperidol was
stopped due to protocol criteria, death or ICU discharge. Each blood
samplewas immediately sent to the hospital pharmacy laboratory, cen-
trifuged, and the serum was stored at−80 °C until haloperidol quanti-
fication using validated, FDA-approved, liquid chromatography-mass
spectrometry methods [17]. All serum concentrations were corrected
for the most recent haloperidol dose administered.
2.3. Data analysis
A prospectively collected convenience sample of 20 patients was
chosen given the study's pilot nature and the lack of available published
ICU data to provide a standard deviation estimate for any of the out-
comes evaluated. Two additional patients were enrolled due to con-
cerns that haloperidol serum concentrations might not be able to be
drawn in all patients.
The primary analysis focused on evaluating pharmacogenomic re-
sponse. The decision for what to adjust for was made in advance. A lin-
earmixedmodelwas constructed that adjusted for age, admission SOFA
score and ICU day to evaluate the association between CYP2D6
metabolizer status (or CYP3A4metabolizer status) and daily serumhal-
operidol trough concentrations. To evaluate pharmacokinetic response,
a third linear mixed model was constructed that adjusted for age, SOFA
and ICU day to evaluate the association between daily haloperidol dose
and daily serum haloperidol trough concentrations. To evaluate phar-
macodynamic response, a fourth linear mixed model was constructed
that adjusted for age, SOFA and ICU day to evaluate the association be-
tween the highest ICDSC score (i.e. delirium severity) and daily serum
haloperidol trough concentrations. Given concerns about model
overfitting, neither CYP2D6 or CYP3A4 metabolizer status were incor-
porated into these last two models. Haloperidol safety was evaluated
by comparing the QTc interval between days and the proportion of pa-
tients where it was prolonged (≥500 msec). Data was presented as per-
centages, median (IQR) or mean (SD). Two-sided p values b.05 were
considered statistically significant. Outliers were excluded from analy-
sis. All analyses were performed using R (additional packages: foreign,
lme4, and rms; R Foundation for Statistical Computing, Vienna,
Austria; http://www.R-project.org/).
3. Results
3.1. Baseline characteristics and clinical outcomes
Twenty-two patients (100% Caucasian, 55% male, 67 [IQR 60, 70]
years old, BMI 27 [IQR 18, 39] kg/m2, APACHE III 81 [IQR 76, 99],
serum BUN 18 ± 13 mmol/L) were enrolled. The primary reason for
ICU admission included: surgery (7, 32%), respiratory failure (3, 14%),
sepsis (3, 14%) and vascular aneurysm (2, 9%). The median length of
ICU stay was 16 [2, 63] days. Eleven patients died (50%); six patients
during the ICU stay, four after ICU discharge, and one after transfer to
another hospital. Thirteen patients (59%) completed the maximum six
days of data collection. Detailed demographic and clinical outcomes
for each patient is presented in E-Table 1.
3.2. Pharmacokinetic and pharmacogenomic outcomes
The 81 trough serum haloperidol concentrations collected are pre-
sented by ICU day in Fig. 1. Seven very high serum haloperidol concen-
trations (≥10 μg/L) were observed in four patients. The median [IQR]
serum haloperidol concentration for 81 samples was 1.9 [1.2 to 3.5]
Table 1
Average ICDSC score, SOFA score and QTc interval on each study day.
Parameter Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
ICDSC scorea 3.8 ± 1.4 5.0 ± 1.1 4.7 ± 1.5 4.9 ± 1.6 4.3 ± 2.1 4.5 ± 1.7 4.5 ± 1.8
SOFA scorea 10.0 ± 3.1 9.0 ± 3.8 9.3 ± 4.3 10 ± 5.1 9.8 ± 5.1 8.4 ± 5.1 9.7 ± 5.3)
QTc interval (msec)a 413 ± 34 423 ± 33 425 ± 27 418 ± 23 413 ± 20 414 ± 36 423 ± 36
ICDSC = Intensive Care Delirium Screening Checklist, SOFA = Sequential Organ Function Assessment.
a Presented as mean ± SD.
205Z. Trogrlić et al. / Journal of Critical Care 57 (2020) 203–207μg/L; for the 72 b 10mg/dL it was b1.7 [1.2 to 2.95] μg/L. Serum concen-
trations for the four patients with at least one sample ≥10 mg/dL
and presence of factors that may have accounted for a serum
concentration ≥10 mg/dL are presented in E-Table 2.
The CYP2D6 genotype analysis revealed: extensive metabolizers
(EM) (12, 54%), intermediate metabolizers (IM) (7, 32%), and poor
metabolizers (PM) (3, 14%). No ultra-rapidmetabolizers were detected.
The daily distribution of serum haloperidol concentrations based on
CYP2D6 metabolizer status is presented in Fig. 2. An association be-
tween serumhaloperidol serumconcentration andCYP2D6metabolizer
status and was not found (IM p = .67/PM p = .25) (E-Table 3). The
CYP3A4 genotype analysis revealed: EM (18, 82%) and IM (4, 18%). No
ultra-rapid metabolizers or PMs were detected. The daily distribution
of serum haloperidol concentrations based on CYP3A4 metabolizer sta-
tus is presented in Fig. 3. An association between serum haloperidol
concentration and CYP3A4 metabolizer status was not found (IM p =
.44) (E-Table 4).
Most (18, 82%) patients received 1 or more concomitant medica-
tions known to inhibit CYP2D6 and many (13, 59%) received 1 or
more concomitant medications known to inhibit CYP3A4. A total of 5
(24%) patients were administered quetiapine (E-Table 1).3.3. Haloperidol dose, delirium severity and QTc interval outcomes
The average daily haloperidol dose, ICDSC score, SOFA score and QTc
interval are presented in Table 1. Themedian [IQR] haloperidol dose ad-
ministered across the six study days (See Fig. 4) was 3.0 [2.4, 4.5] mg
andwas not different between individual studydays (p=.28). After ad-
justment for ICU day, age, daily SOFA score, an association betweenFig. 1. Observed haloperidol trough concentrations per patient per day.haloperidol dose and serum haloperidol concentration was not found
(p = .77). The outputs for this linear mixed model are described in
E-Table 5.
An association between the haloperidol serum concentration and
delirium severity (based on ICDSC score was not found (p = .20).
After adjustment for ICU day, age, daily SOFA score, an association be-
tween serum haloperidol concentration and delirium severity was also
not found (p = .13). The outputs for this linear mixed model are de-
scribed in E-Table 6.
Among the 92 ECGs performed, the QTc interval ranged from 318
and 486 msec; none exceeded 500 ms. The average QTc interval was
not different between day 1 (423 ± 33 ms) and day 5 (413 ± 20 ms)
(p = .48).
4. Discussion
This single-center prospective observational pilot study is the first to
evaluate the pharmacogenomics of low-dose haloperidol in critically ill
adults with delirium. Our results suggest that neither CYP2D6 or
CYP3A4 genotype status has an important effect on serum haloperidol
concentrations in critically ill adults despite a CYP3A4 extensive
metabolizer status prevalence (82%) in our critically ill cohort that is
higher than that reported in healthy Caucasians (55%) [8]. Scheduled
IV haloperidol at a dose of up 2 mg q8h does not appear to affect delir-
ium symptoms based on the ICDSC assessments evaluated. The lack of a
relationship we observed between measured serum haloperidol con-
centrations and the dose of haloperidol administered suggests that im-
portant factors other than age, severity of illness, ICU day of
administration and CYP2D6/CYP3A4 isoenzyme status likely accountFig. 2. Daily distribution of haloperidol serum concentrations on each study day based on
CYP2D6 metabolizer status.
Fig. 3. Daily distribution of haloperidol serum concentrations on each study day based on
CYP3A4 metabolizer status.
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observed.
While our data is consistent with a recent pharmacokinetic sec-
ondary analysis from the REDUCE trial, it is important to recognize
the REDUCE analysis evaluated haloperidol use in patients without
delirium and did not assess pharmacogenomic considerations like cy-
tochrome P450 isoenzyme genotype [6]. It remains unclear if the lack
of haloperidol benefit observed in our cohort is simply a result of the
subtherapeutic haloperidol concentrations detected, an intrinsic lack
of response of delirium to haloperidol, or related to the often fluctu-
ating, time varying nature of delirium. Until these complex relation-
ships are further studied, clinicians should have a low threshold
level to increase the dose of haloperidol being administered to ICU
patients with delirium symptoms severe enough to warrant haloper-
idol administration.Fig. 4. Average haloperidol dose aThe results of two recent clinical trials in critically ill patients receiv-
ing low-dose haloperidol therapy have also reported a lack of effect on
delirium resolution, and suggests subtherapeutic serum concentrations
are an important reason for this observed lack of effect [1,4]. However,
the MIND trial [3], where haloperidol was administered at a dose of 15
mg/day, the median [IQR] serum haloperidol trough concentration on
study day two of 4.5 [2.9, 5.8] μg/L. Despite patients in the MIND trial
achieving a serum tough concentration nearly three-times higher than
that observed in our cohort, use of haloperidol was not associated
with fewer days spent with delirium. The recent MIND-USA trial
found that the administration of even IV haloperidol doses (up to 20
mg/day) not to be associated with delirium resolution or reduced mor-
tality. This suggests haloperidol may not have any intrinsic effect on de-
lirium, regardless of the dose administered or the serum concentrations
achieved [18].
Outside of the ICU setting, the therapeutic window for haloperidol
response in patients with acute schizophrenia has been reported to
range from 5.6 to 16.9 μg/L. In this population, the recommended target
concentration is 10 of μg/L [10]. Whether the therapeutic dose required
in schizophrenia is similar to the dose needed to treat ICU-delirium re-
mains unclear. A recent paediatric ICU study suggests low dose haloper-
idol may reduce delirium despite the low serum concentrations
achieved [19].
Our study has limitations. It was neither controlled nor blinded.
Although patientswith factors that could influence the clinical, pharma-
cokinetic or genomic outcomes evaluated were excluded, the heteroge-
nous nature of any ICU population may have confounded our results.
Given the variability between patients we observed, future investiga-
tions should focus on evaluating larger numbers of patients and at a
greater range of haloperidol doses. Although seeking to conduct as prag-
matic investigation as possible, some patients received one or more
medications known to affect haloperidol serum concentrations. While
haloperidol concentrations were not measured in the ICU before the
first dose of haloperidol was administered, the investigators reviewed
each patient record to ensure haloperidol had not been previously ad-
ministered during the hospitalization. The potential reasons for the
very high serum haloperidol concentrations observed in four patients
were carefully evaluated. The fact that no patients had poormetabolizer
status for both CYP2D6 and CYP3A4 precluded our ability tomodel a po-
tential interaction between these combined poor metabolizer statuses
in our analysis. Finally, in a study evaluating only 22 patients it may
be possible that an association between CYP2D6/CYP3A4 isoenyzymedministered each study day.
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concentrations do exist despite the lack of association we observed.
Future studies evaluating the pharmacokinetics and -dynamics of
haloperidol in critically ill adults should seek to define clearance, area-
under-the-curve, and volume of distribution volume when testing hal-
operidol efficacy in critically ill adults. More extensive pharmacokinetic
studies conducted at serum state concentrations and pharmacogenetic
studies that control for the effects of critical illness on CYP activity are
clearly indicated. Future ICU studies should focus on the presence of in-
dividual delirium symptoms with haloperidol use rather than delirium
simply being either present or absent.5. Conclusions
This report represents the first prospective study to evaluate the
pharmacogenetic parameters of low-dose intravenous haloperidol
when used for the treatment of delirium symptoms in critically ill
adults. The lack of response observed with haloperidol use may be re-
lated to lower than expected serum concentrations, although we were
not able to identify specific pharmacokinetic or pharmacogenomic fac-
tors accounting for this finding. It also may be possible that haloperidol
is ineffective for the treatment of ICU delirium. How these factors ac-
count for the lack of clinical efficacy observed in recent randomized tri-
als evaluating the use of low-dose haloperidol in critically ill adults
remains unclear.Funding
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